摘要
目的探讨非小细胞肺癌患者外周血EGFR检测的临床意义。方法回顾性分析49例经病理证实为非小细胞肺癌患者的临床资料,患者均通过高通量测序法行外周血EGFR检测,分析有无EGFR突变与性别、年龄、吸烟史、病理分型和分期以及药物治疗后病情的关系。结果不同性别、年龄组的EGFR突变率比较差异均无统计学意义(P>0.05);吸烟组的EGFR突变率高于不吸烟组(P<0.05)。不同病理分型及分期肺癌的EGFR突变率比较,差异均有统计学意义(P<0.05)。EGFR无突变组服药后进展率高于EGFR突变组,差异有统计学意义(P<0.01)。结论 EGFR突变与患者的性别、年龄无关,与吸烟、病理分型及分期有关,EGFR突变者服药后疗效高于无突变者。
Objective To investigate clinical significance on epidermal growth factor receptor(EGFR)of peripheral blood in patients with non-small cell lung cancer(NSCLC). Methods Clinical data of 49 patients pathologically confirmed with NSCLC were retrospectively analysed.High-throughput sequencing were used to detect EGFR mutation state in all patients′ peripheral blood.The relationship between whether EGFR mutation and sex,age,smoking history,pathological type and pathological stage,condition after drug treatment were analysed. Results EGFR mutation rate of different gender,age group was compared respectively,with no statistical difference(P〉0.05).EGFR mutation rate in smoking group was higher than that in non-smoking group(P〈0.05).EGFR mutation rate of different pathological type and pathological stage was compared respectively,with statistical difference(P〈0.05).The progress rate of EGFR non-mutation group after taking was higher than that of EGFR mutant group,with statistical difference(P〈0.01). Conclusion EGFR mutation is not associated with sex and age,is related to smoking,pathological type and pathological stage.The curative effect of patients with EGFR mutation is better than that non-mutation after taking the drug.
出处
《中国当代医药》
2014年第35期131-132,137,共3页
China Modern Medicine
关键词
非小细胞肺癌
外周血EGFR
突变
临床意义
Non-small cell lung cancer
Epidermal growth factor receptor of peripheral blood
Mutation
Clinical significance